Skip to content

Celcuity CELC Total debt

Total debt at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.26B+32,101%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$31.57M-33.1%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$15.48M-9.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$32.79M-11.3%
Eli Lilly logo
Eli LillyLLY
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Calculated from Celcuity’s reported figures.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's total debt?
Celcuity (CELC) reported total debt of $137.89M in Q1 2026.
How has Celcuity's total debt changed year-over-year?
Celcuity's total debt increased by 30.7% year-over-year, from $105.52M to $137.89M.
What is the long-term trend for Celcuity's total debt?
Over 5 years (2020 to 2025), Celcuity's total debt has grown at a 239.0% compound annual growth rate (CAGR), from $307.19K to $137.6M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.